Efficacy of infliximab in pediatric Crohn's disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

Inflammatory Bowel Diseases

Volumn 15, Issue 3, 2009, Pages 388-394

  Ruemmele, Frank M ^a,b   Lachaux, Alain ^c   Cézard, Jean Pierre ^d   Morali, Alain ^e   Maurage, Chantal ^f   Giniès, Jean Louis ^g   Viola, Sheila ^h   Goulet, Olivier ^a,b   Lamireau, Thierry ⁱ   Scaillon, Michèle ^j   Breton, Anne ^k   Sarles, Jacques ^l  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e HÔPITAL D ENFANTS   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j FREE UNIVERSITY OF BRUSSELS   (Belgium)

^k HÔPITAL DES ENFANTS   (France)

^l TIMONE HOSPITAL   (France)

more..

Author keywords

Efficacy; Infliximab; Pediatric Crohn's disease; Safety

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ERYTHROCYTE SEDIMENTATION RATE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; CHILD; COLONOSCOPY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; COLONOSCOPY; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 66149096693     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20788     Document Type: Article

References (36)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
2. Podolsky D. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521.
4. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
5. Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet. 2008;9:9-14.
6. Yamamoto-Furusho JK, Podolsky DK. Innate immunity in inflammatory bowel disease. World J Gastroenterol. 2007;13:5577-5580.
7. Wehkamp J, Stange EF. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense. Ann N Y Acad Sci. 2006; 1072:321-331.
8. Korzenik JR. Is Crohn's disease due to defective immunity? Gut. 2007; 56:2-5.
9. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
10. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455-1466.
11. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387-398.
12. Merger M, Viney JL, Borojevic R, et al. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut. 2002;51:155-163.
13. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997;27:1743-1750.
14. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet. 1993;342:173-174.
15. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608.
16. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997. 9;337:1029-1035.
17. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
18. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-838.
19. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2003;36:632-636.
20. Lamireau T, Cézard JP, Dabadie A, et al, French-Speaking Group for Pediatric Gastroenterology Nutrition. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004;10:745-750.
21. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002; 97:1408-1414.
22. Wynands J, Belbouab R, Candon S, et al. 12-Month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46:293-299.
23. Hanauer SB, Feagan BG, Lichtenstein GR, et al, ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
24. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
25. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children (REACH study). Gastroenterology. 2007;132:863-873.
26. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
27. Gower-Rousseau C Salomez JL, Dupas JL, Marti R, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994; 35:1433-1438.
28. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
29. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-347.
30. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196.
31. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
32. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther. 2003;18:425-431.
33. Afzal NA, Ozzard A, Keady S, et al. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig Dis Sci. 2007;52:3329-3333.
34. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030.
35. Cucchiara S, Escher JC, Hildebrand H, et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr. 2008 (in press).
36. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134: 1861-1868.